NLNing Lin

Ning Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ning Lin has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Dazhi Zhang

    Department of Infectious Disease the Second Affiliated Hospital of Chongqing Medical University Chongqing China

    1 shared publication
  • Hong Wu

    The Department of Liver Surgery & Liver Transplantation Centre West China Hospital, Sichuan University Sichuan China

    1 shared publication
  • Huiguo Ding

    Department of Gastroenterology and Hepatology, Beijing You’an Hospital Affiliated with Capital Medical University, Beijing, China

    1 shared publication
  • Jia Shang

    Department of Infectious Diseases Henan Provincial People's Hospital Henan China

    1 shared publication
  • Jiaping Li

    Department of Interventional Oncology The First Affiliated Hospital, Sun Yat‐sen University Guangdong China

    1 shared publication
  • Jifang Sheng

    State Key Laboratory for Diagnosis and Treatment of Infectious Diseases The First Affiliated Hospital, Zhejiang University School of Medicine Zhejiang China

    1 shared publication

Latest Publications

  • Open Access

    Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

    by Yifan Han, Ning Lin, Jinghang Xu, Sikui Wang, Jinglan Jin, Jia Shang, Yongning Xin, Youwen Tan, Dazhi Zhang, Jinlin Hou, et al.

    Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive procedures. In this multicenter, randomized (2:1), double‐blind, placebo‐controlled phase III trial, 120 adult Chinese patients with CLD‐related thrombocytopenia (platelet count < 50 × 10 9 /L) received rhTPO ( n = 80) or placebo ( n = 40) once daily for up to 5 or 7 days. The primary endpoint was the proportion of patients with sustained platelet counts ≥ 50 × 10 9 /L from 24 h before invasive procedure to 7 days post‐procedure, without requiring emergency bleeding management. The primary endpoint was achieved by 85.0% of patients in the rhTPO group versus 12.5% in the placebo group ( p < 0.0001). Preoperatively, platelet counts ≥ 50 × 10 9 /L were achieved in 92.5% and 20.0% of patients in the rhTPO and placebo groups, respectively ( p < 0.0001). Platelet transfusion was avoided in 92.5% of rhTPO‐treated patients versus 25.0% of placebo‐treated patients ( p < 0.0001). The median duration of platelet counts ≥ 50 × 10 9 /L was significantly longer with rhTPO than with placebo (21.0 vs. 3.0 days, p = 0.0007). Treatment‐related treatment‐emergent adverse events (TEAEs) occurred in 12.5% of patients in both the rhTPO and placebo groups. No treatment‐related serious adverse events were reported. Overall, rhTPO was effective and well tolerated in patients with CLD‐related thrombocytopenia and may represent a viable therapeutic option for those undergoing elective invasive procedures. Trial Registration: www.chinadrugtrials.org.cn : number CTR20230919.